Fidelis Capital Partners LLC Cuts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Fidelis Capital Partners LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,146 shares of the medical research company’s stock after selling 195 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,848,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TMO. Epoch Investment Partners Inc. increased its stake in Thermo Fisher Scientific by 1.7% in the 2nd quarter. Epoch Investment Partners Inc. now owns 323,268 shares of the medical research company’s stock valued at $178,767,000 after purchasing an additional 5,295 shares in the last quarter. Frank Rimerman Advisors LLC increased its position in shares of Thermo Fisher Scientific by 19,058.3% in the second quarter. Frank Rimerman Advisors LLC now owns 4,598 shares of the medical research company’s stock valued at $2,543,000 after buying an additional 4,574 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 12.8% during the 2nd quarter. ProShare Advisors LLC now owns 59,607 shares of the medical research company’s stock worth $32,963,000 after buying an additional 6,783 shares during the last quarter. Alaethes Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 3.0% in the 2nd quarter. Alaethes Wealth LLC now owns 3,093 shares of the medical research company’s stock worth $1,711,000 after buying an additional 90 shares in the last quarter. Finally, Legacy Financial Advisors Inc. increased its holdings in Thermo Fisher Scientific by 7.3% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 2,115 shares of the medical research company’s stock valued at $1,170,000 after acquiring an additional 144 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on TMO. Bank of America increased their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Wells Fargo & Company initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target for the company. TD Cowen increased their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Raymond James raised their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $647.78.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock worth $14,094,292 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $613.69 on Friday. The firm has a market capitalization of $234.26 billion, a PE ratio of 39.36, a P/E/G ratio of 2.86 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The business has a 50-day moving average of $599.56 and a two-hundred day moving average of $581.45.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.